Making a Cure Possible —
Bringing Blood Stem Cells to the Forefront of Medicine
Pioneering a future where blood stem cell therapies safely and routinely cure disease.
We are transforming the conditioning step of hematopoietic stem cell transplantation (HSCT) to make curative treatments safer, more precise, and widely accessible. Conditioning – the first phase of treatment – continues to rely on decades old chemotherapy and radiation, which are associated with significant toxicities. By replacing these approaches with targeted biologic conditioning, we aim to remove barriers that limit access to life-saving therapies and unlock the full potential of stem-cell and gene-based medicine.
Unlocking the Full Potential of a Proven Curative Therapy
HSCT
Hematopoietic stem cell transplantation has been a powerful, clinically validated therapy for over 50 years, delivering life-changing outcomes for patients with hematologic cancers, genetic blood disorders, and severe autoimmune diseases – and, more recently, to promote immune tolerance in solid organ transplantation.
Despite its curative potential, HSCT remains significantly underutilized. In the U.S. alone, over a million people are living with diseases that could potentially be addressed by stem cell transplantation.
The procedure begins with conditioning, typically using high-dose chemotherapy and/or radiation to prepare the bone marrow for transplant. Once this procedure is complete, healthy stem cells are infused into the patient, where they engraft in the marrow and regenerate the patient’s blood and immune systems.
However, current conditioning methods can cause significant toxicities – including infertility, organ damage, secondary cancers, and treatment-related mortality – which limit their use and restrict access to fewer than 10% of eligible patients.
